{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:12:29Z","timestamp":1788307949772,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017633","name":"Shanghai Anti Cancer Association","doi-asserted-by":"publisher","award":["SHAX-QT-202101"],"award-info":[{"award-number":["SHAX-QT-202101"]}],"id":[{"id":"10.13039\/100017633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinthera.2024.09.019","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T18:59:52Z","timestamp":1729364392000},"page":"1049-1058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2177-326X","authenticated-orcid":false,"given":"Wensheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-9704","authenticated-orcid":false,"given":"Qiong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.019_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.757196","article-title":"Safety profile of oxaliplatin in 3,687 patients with cancer in China: a post-marketing surveillance study","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0002","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.3390\/pharmaceutics15112620","article-title":"Colorectal cancer: disease process, current treatment options, and future perspectives","volume":"15","author":"Adebayo","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114304","article-title":"A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer","volume":"160","author":"Xie","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0004","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40199-020-00374-5","article-title":"Development, optimization and in vitro evaluation of oxaliplatin loaded nanoparticles in non-small cell lung cancer","volume":"28","author":"Esim","year":"2020","journal-title":"Daru"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0005","first-page":"603","article-title":"NCCN guidelines updates: pancreatic cancer","volume":"17","author":"Tempero","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0006","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1186\/s12885-021-09027-5","article-title":"Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases","volume":"21","author":"Shi","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0007","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jamaoncol.2022.7136","article-title":"Rechallenge after oxaliplatin-induced hypersensitivity reactions","volume":"9","author":"Rassy","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0008","doi-asserted-by":"crossref","first-page":"15410","DOI":"10.3390\/ijms232315410","article-title":"Revisiting the anti-cancer toxicity of clinically approved platinating derivatives","volume":"23","author":"Forgie","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.clcc.2011.10.004","article-title":"Literature review and practical aspects on the management of oxaliplatin-associated toxicity","volume":"11","author":"Hoff","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","article-title":"FDA drug approval summaries: oxaliplatin","volume":"9","author":"Ibrahim","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0011","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.3390\/jcm11164770","article-title":"Corneal nerve changes observed by in vivo confocal microscopy in patients receiving oxaliplatin for colorectal cancer: the COCO study","volume":"11","author":"Tyler","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0012","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/cancers16020344","article-title":"Ocular surface side effects of novel anticancer drugs","volume":"16","author":"Vitiello","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2024.09.019_bib0013","first-page":"ii84","article-title":"Ocular toxicities with oxaliplatin in colorectal cancer","volume":"25","author":"Una","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cpt.2920","article-title":"Tumor lysis syndrome associated with monoclonal antibodies in patients with multiple myeloma: a pharmacovigilance study based on the FAERS database","volume":"114","author":"Xia","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0015","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA Adverse Event Reporting System Database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40259-018-0285-2","article-title":"Safety of biologics approved for the treatment of rheumatoid arthritis and other autoimmune diseases: a disproportionality analysis from the FDA Adverse Event Reporting System (FAERS)","volume":"32","author":"Araujo","year":"2018","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0019","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)","volume":"24","author":"Zou","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0020","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0021","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"International Society of Pharmacoepidemiology; International Society of Pharmacovigilance. Guidelines for submitting adverse event reports for publication","volume":"30","author":"Kelly","year":"2007","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000521842","article-title":"Amaurosis fugax: a rare oxaliplatin-induced ocular toxicity\u2014a report of three cases","volume":"15","author":"Tunio","year":"2022","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0023","first-page":"e4582","article-title":"Reversible ocular toxicity of oxaliplatin: a case report","volume":"11","author":"Noor","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1188\/06.CJON.227-229","article-title":"Ocular changes with oxaliplatin","volume":"10","author":"O'Dea","year":"2006","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000322675","article-title":"Oxaliplatin-related ocular toxicity","volume":"3","author":"Mesquida","year":"2010","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0026","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1159\/000516271","article-title":"Oxaliplatin-associated amaurosis fugax","volume":"14","author":"Kubo","year":"2021","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0027","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1177\/10781552211004985","article-title":"Motor \u201cfreezing\u201d with oxaliplatin","volume":"27","author":"Patel","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0028","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/15569527.2014.944647","article-title":"Idiopathic intracranial hypertension and oxaliplatin: a causal association?","volume":"34","author":"Painhas","year":"2015","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000514656","article-title":"Transient vision loss\u2014a rare oxaliplatin-induced ophthalmologic side effect: a report of two cases","volume":"14","author":"Ah-Thiane","year":"2021","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0030","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1016\/j.jfo.2020.10.013","article-title":"A case of oxaliplatin-related toxic optic neuropathy","volume":"44","author":"Beaumont","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0031","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1078155209104383","article-title":"Blepharoptosis following oxaliplatin administration","volume":"15","author":"Lau","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0032","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1177\/030089161309900516","article-title":"Reversible bilateral blepharoptosis following oxaliplatin infusion: a case report and literature review","volume":"99","author":"Fanetti","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0033","doi-asserted-by":"crossref","unstructured":"La Verde N, Garassino MC, Spinelli G, et al. Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis. 2007;39:1041.","DOI":"10.1016\/j.dld.2007.07.162"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0034","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1078155211401455","article-title":"Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection","volume":"18","author":"Gilbar","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0035","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-5-116","article-title":"Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer","volume":"5","author":"Leonard","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0036","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1078155219886640","article-title":"Optic neuritis induced by 5-fluorouracil chemotherapy: case report and review of the literature","volume":"26","author":"Raina","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0037","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00002018-200124050-00002","article-title":"Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer","volume":"24","author":"Jansman","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0038","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/jns5.12036","article-title":"Corneal confocal microscopy in patients with oxaliplatin-induced peripheral neuropathy","volume":"18","author":"Campagnolo","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0039","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/tvst.10.1.24","article-title":"A cross-sectional study of sub-basal corneal nerve reduction following neurotoxic chemotherapy","volume":"10","author":"Chiang","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.clinthera.2024.09.019_bib0041","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.survophthal.2005.11.001","article-title":"Update on ocular complications of systemic cancer chemotherapy","volume":"51","author":"Schmid","year":"2006","journal-title":"Surv Ophthalmol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:00:46Z","timestamp":1733860846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0149291824002820"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.019","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the Spectrum of Ocular Toxicity with Oxaliplatin: Clinical Feature Analysis of Cases and Pharmacovigilance Assessment of the US Food and Drug Administration Adverse Event Reporting System Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}